Nesiritide for Ventilated Congestive Heart Failure

NCT04455477 | Unknown

• 1 other identifier: B2020-056R
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The congestive heart failure is a common disease among patients who receive cardiac surgery and may lead to prolonged ventilation support. Nesiritide was a potential therapy for congestive heart failure. This study aimed to compare the Nesiritide induced hemodynamical status changes among congestive heart failure patients with invasive ventilation support.

Conditions

Congestive Heart Failure; Mechanical Ventilation; Using Nesiritide; Venous Return; Cardiac Function

Keywords

Congestive Heart Failure; Nesiritide

Outcome Measures

Primary Outcomes (2)

• Changes of cardiac output

  Changes of cardiac output measured by hemodynamical monitoring tools

  Before and 30-min after using a standard dose of Nesiritide

• Changes of systemic filling pressure

  Changes of the intercept of regression line of paired VR-RAP points at different PEEP levels.

  Before and 30-min after using a standard dose of Nesiritide

Secondary Outcomes (2)

• Changes of cardiac function curve

  Before and 30-min after using a standard dose of Nesiritide

• Changes of venous return curve

  Before and 30-min after using a standard dose of Nesiritide

Interventions

Nesiritide DRUG

The attending physicans decide whether to use Nesiritide for congestive heart failure patients. Only patients who will use Nesiritide are enrolled.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Congestive heart failure patients relying on mechanical ventilation and therefore decide to try the Nesiritide.

You may qualify if:

• Age≥18 years；
• Congestive Heart Failure;
• With mechanical ventilation；
• With hemodynamic monitoring devices;
• The physicians made the decision of using Nesiritide.

You may not qualify if:

• Unstable hemodynamic status；
• Severe renal dysfunction.

Sponsors & Collaborators

• Shanghai Zhongshan Hospital: lead

Study Sites (1)

Zhongshan Hospital

Xuhui, Shanghai Municipality, 200032, China

RECRUITING

MeSH Terms

Conditions

Heart Failure

Interventions

Natriuretic Peptide, Brain

Condition Hierarchy (Ancestors)

Heart Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Natriuretic Peptides; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Peptides; Amino Acids, Peptides, and Proteins; Nerve Tissue Proteins; Proteins

Central Study Contacts

Zhe Luo, MD

CONTACT

+8613916127028; luo.zhe@zs-hospital.sh.cn

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 16, 2020
• First Posted: July 2, 2020
• Study Start: May 14, 2020
• Primary Completion: December 31, 2021
• Study Completion: December 31, 2021
• Last Updated: July 2, 2020

Record last verified: 2020-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)